• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Relapsed/Refractory ETP-ALL Successfully Treated With Venetoclax and Nelarabine as a Bridge to Allogeneic Stem Cell Transplant.

作者信息

McEwan Ashley, Pitiyarachchi Omali, Viiala Nicholas

机构信息

Department of Hematology, Liverpool Hospital, Sydney, Australia.

Chris O'Brien Lifehouse, Department of Medical Oncology, Sydney, Australia.

出版信息

Hemasphere. 2020 Jun 8;4(3):e379. doi: 10.1097/HS9.0000000000000379. eCollection 2020 Jun.

DOI:10.1097/HS9.0000000000000379
PMID:32647798
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7306301/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9751/7306301/0537054a6e84/hs9-4-e379-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9751/7306301/0537054a6e84/hs9-4-e379-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9751/7306301/0537054a6e84/hs9-4-e379-g001.jpg

相似文献

1
Relapsed/Refractory ETP-ALL Successfully Treated With Venetoclax and Nelarabine as a Bridge to Allogeneic Stem Cell Transplant.复发/难治性早期T细胞前体急性淋巴细胞白血病经维奈克拉和奈拉滨成功治疗作为异基因干细胞移植的桥梁
Hemasphere. 2020 Jun 8;4(3):e379. doi: 10.1097/HS9.0000000000000379. eCollection 2020 Jun.
2
The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia: literature review and own experience.奈拉滨在治疗T细胞急性淋巴细胞白血病中的作用：文献综述及自身经验
Ter Arkh. 2018 Aug 17;90(7):38-50. doi: 10.26442/terarkh201890738-50.
3
Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience.在复发/难治性CD30阳性淋巴细胞增殖性疾病中，使用本妥昔单抗作为异基因干细胞移植前的挽救治疗：单中心经验。
Intern Med J. 2017 May;47(5):574-578. doi: 10.1111/imj.13415.
4
Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant.维奈托克联合地西他滨用于异基因造血细胞移植后复发的T细胞急性淋巴细胞白血病
Case Rep Hematol. 2018 Aug 26;2018:6092646. doi: 10.1155/2018/6092646. eCollection 2018.
5
Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience.维奈托克联合疗法治疗复发/难治性急性髓系白血病：单机构经验
Leuk Res. 2020 Mar;90:106314. doi: 10.1016/j.leukres.2020.106314. Epub 2020 Jan 30.
6
Nelarabine-associated reversible Guillain-Barré-like syndrome or myelopathy in an adult patient with primary refractory T-lymphoblastic lymphoma.一名原发性难治性T淋巴细胞母细胞淋巴瘤成年患者出现与奈拉滨相关的可逆性吉兰-巴雷综合征样综合征或脊髓病。
Curr Probl Cancer. 2017 Mar-Apr;41(2):138-143. doi: 10.1016/j.currproblcancer.2016.11.005. Epub 2016 Nov 17.
7
Nelarabine neurotoxicity with concurrent intrathecal chemotherapy: Case report and review of literature.奈拉滨神经毒性合并鞘内化疗：病例报告及文献综述
J Oncol Pharm Pract. 2015 Aug;21(4):296-300. doi: 10.1177/1078155214528018. Epub 2014 Mar 24.
8
BCL2 Inhibition by Venetoclax: Targeting the Achilles' Heel of the Acute Myeloid Leukemia Stem Cell? Venetoclax 抑制 BCL2：靶向急性髓系白血病干细胞的阿喀琉斯之踵？
Cancer Discov. 2016 Oct;6(10):1082-1083. doi: 10.1158/2159-8290.CD-16-0921.
9
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Venetoclax 治疗伴有 17p 缺失的复发或难治性慢性淋巴细胞白血病：一项多中心、开放标签、2 期研究。
Lancet Oncol. 2016 Jun;17(6):768-778. doi: 10.1016/S1470-2045(16)30019-5. Epub 2016 May 10.
10
Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.通过靶向异常的PI3K/AKT/mTOR信号通路提高奈拉滨在T细胞急性淋巴细胞白血病中的疗效。
J Hematol Oncol. 2016 Oct 24;9(1):114. doi: 10.1186/s13045-016-0344-4.

引用本文的文献

1
Daratumumab and venetoclax combined with CAGE for late R/R T-ALL/LBL patients: Single-arm, open-label, phase I study.达雷妥尤单抗与维奈克拉联合 CAGE 方案治疗晚期复发/难治性 T 细胞急性淋巴细胞白血病/淋巴母细胞淋巴瘤患者：单臂、开放标签、I 期研究。
Ann Hematol. 2024 Aug;103(8):2993-3004. doi: 10.1007/s00277-024-05775-z. Epub 2024 Apr 25.
2
A Comparative Analysis of Early T-Cell Precursor Lymphoblastic Leukemia/Lymphoma (ETP-ALL/LBL) and Non-ETP-ALL/LBL in a Tertiary Cancer Care Center Based in Western India.印度西部一家三级癌症护理中心对早期T细胞前体淋巴细胞白血病/淋巴瘤（ETP-ALL/LBL）和非ETP-ALL/LBL的比较分析
Indian J Hematol Blood Transfus. 2023 Oct;39(4):699-704. doi: 10.1007/s12288-023-01627-4. Epub 2023 Jan 12.
3

本文引用的文献

1
Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. Venetoclax 联合化疗治疗复发或难治性 T 细胞急性淋巴细胞白血病的临床经验。
Clin Lymphoma Myeloma Leuk. 2020 Apr;20(4):212-218. doi: 10.1016/j.clml.2019.09.608. Epub 2019 Sep 30.
2
Next-Generation Sequencing in Acute Lymphoblastic Leukemia.急性淋巴细胞白血病中的二代测序。
Int J Mol Sci. 2019 Jun 15;20(12):2929. doi: 10.3390/ijms20122929.
3
First report of clinical response to Venetoclax in Early T-cell Precursor Acute Lymphoblastic Leukemia.
Pegaspargase, venetoclax, and nelarabine: a successful bridge to allogeneic hematopoietic stem cell transplantation in a relapsed/refractory T-cell acute lymphoblastic leukemia patient.
培门冬酶、维奈克拉和奈拉滨：一名复发/难治性T细胞急性淋巴细胞白血病患者成功过渡到异基因造血干细胞移植的桥梁。
Ann Hematol. 2023 Jun;102(6):1599-1600. doi: 10.1007/s00277-023-05231-4. Epub 2023 Apr 26.
4
Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia.MERTK和BCL-2在T细胞和早期T前体急性淋巴细胞白血病中的治疗靶向作用
Cancers (Basel). 2022 Dec 13;14(24):6142. doi: 10.3390/cancers14246142.
5
Targeting Leukemia-Initiating Cells and Leukemic Niches: The Next Therapy Station for T-Cell Acute Lymphoblastic Leukemia?靶向白血病起始细胞和白血病微环境：T细胞急性淋巴细胞白血病的下一个治疗靶点？
Cancers (Basel). 2022 Nov 17;14(22):5655. doi: 10.3390/cancers14225655.
6
Novel Treatments for Pediatric Relapsed or Refractory Acute B-Cell Lineage Lymphoblastic Leukemia: Precision Medicine Era.小儿复发性或难治性急性B细胞系淋巴细胞白血病的新型治疗方法：精准医学时代
Front Pediatr. 2022 Jun 23;10:923419. doi: 10.3389/fped.2022.923419. eCollection 2022.
7
Integration of Transcriptome and Interactome Predicts an ETP-ALL-Specific Transcriptional Footprint that Decodes its Developmental Propensity.转录组与相互作用组的整合预测了一种ETP-ALL特异性转录足迹，该足迹可解码其发育倾向。
Front Cell Dev Biol. 2022 May 13;10:899752. doi: 10.3389/fcell.2022.899752. eCollection 2022.
8
The New Therapeutic Strategies in Pediatric T-Cell Acute Lymphoblastic Leukemia.小儿 T 细胞急性淋巴细胞白血病的新治疗策略。
Int J Mol Sci. 2021 Apr 26;22(9):4502. doi: 10.3390/ijms22094502.
维奈托克治疗早期T细胞前体急性淋巴细胞白血病临床反应的首例报告
JCO Precis Oncol. 2018;2. doi: 10.1200/PO.18.00127. Epub 2018 Aug 22.
4
Loss Enhances HSC Self-Renewal Driving Tumor Initiation and Leukemia Stem Cell Activity in T-ALL.缺失增强了 HSC 的自我更新，从而驱动 T-ALL 中的肿瘤起始和白血病干细胞活性。
Cancer Discov. 2019 Mar;9(3):436-451. doi: 10.1158/2159-8290.CD-18-1005. Epub 2018 Dec 19.
5
T cell acute lymphoblastic leukemia (T-ALL): New insights into the cellular origins and infiltration mechanisms common and unique among hematologic malignancies.T 细胞急性淋巴细胞白血病（T-ALL）：血液恶性肿瘤中共同和独特的细胞起源和浸润机制的新见解。
Blood Rev. 2018 Jan;32(1):36-51. doi: 10.1016/j.blre.2017.08.006. Epub 2017 Aug 15.
6
Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype.青少年及成人早期T细胞前体急性淋巴细胞白血病/淋巴瘤（ETP-ALL/LBL）：一种高危亚型
Blood. 2016 Apr 14;127(15):1863-9. doi: 10.1182/blood-2015-08-661702. Epub 2016 Jan 8.
7
ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia.ABT-199 通过抑制 BCL-2 作为 T 细胞急性淋巴细胞白血病的一种新的治疗策略。
Blood. 2014 Dec 11;124(25):3738-47. doi: 10.1182/blood-2014-05-574566. Epub 2014 Oct 9.
8
Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199.T细胞急性淋巴细胞白血病的成熟阶段决定了对BCL-2与BCL-XL的依赖性以及对ABT-199的敏感性。
Cancer Discov. 2014 Sep;4(9):1074-87. doi: 10.1158/2159-8290.CD-14-0353. Epub 2014 Jul 3.
9
Fatal neurological side-effects with necrosis of spinal cord following nelarabine treatment in a child with relapsed T-cell acute lymphoblastic leukemia.一名复发的T细胞急性淋巴细胞白血病患儿在接受奈拉滨治疗后出现致命的神经系统副作用并伴有脊髓坏死。
Am J Hematol. 2013 Dec;88(12):1096-7. doi: 10.1002/ajh.23550. Epub 2013 Sep 12.
10
Lessons from next-generation sequencing analysis in hematological malignancies.血液恶性肿瘤下一代测序分析的启示。
Blood Cancer J. 2013 Jul 19;3(7):e127. doi: 10.1038/bcj.2013.26.